title: Trends in the incidence of transient ischemic attacks, premorbid risk factors and the use of preventive treatments in the population of Dijon, France from 1985 to 2004.
abstract: BACKGROUND
  We describe the epidemiological trends of transient ischemic attack (TIA) in a 20-year population-based pilot study.
  
  
  METHODS
  Trends in the incidence, risk factors and pre-TIA use of preventive treatments for TIA were observed from 1985 to 2004 according to the classic definition in the population of the city of Dijon, France (150,000 inhabitants).
  
  
  RESULTS
  The raw and standardized incidence of TIA were stable over time. We observed a significant increase in the mean age at TIA onset in women only. The prevalence of hypercholesterolemia and diastolic blood pressure > or =90 mm Hg among patients with TIA increased significantly. This contrasts with falls in smoking and in history of previous myocardial infarction.
  
  
  CONCLUSIONS
  The stability of classic TIA incidence, despite the rise in the proportion of elderly people, and the increase in the mean age at onset in women may be considered as a medical progress.
authors.affiliation: Stroke Registry of Dijon, INSERM and Institut de Veille Sanitaire, Faculty of Medicine and University Hospital of Dijon, Dijon, France.
authors.forename: Yannick
authors.initials: Y
authors.lastname: Bejot
authors.forename: Olivier
authors.initials: O
authors.lastname: Rouaud
authors.forename: Isabelle
authors.initials: I
authors.lastname: Benatru
authors.forename: Jérôme
authors.initials: J
authors.lastname: Durier
authors.forename: Marie
authors.initials: M
authors.lastname: Caillier
authors.forename: Grégory
authors.initials: G
authors.lastname: Couvreur
authors.forename: Agnès
authors.initials: A
authors.lastname: Fromont
authors.forename: Nicolas
authors.initials: N
authors.lastname: Falvo
authors.forename: Guy-Victor
authors.initials: GV
authors.lastname: Osseby
authors.forename: Yves
authors.initials: Y
authors.lastname: Cottin
authors.forename: Marianne
authors.initials: M
authors.lastname: Zeller
authors.forename: Emilie
authors.initials: E
authors.lastname: Millerot
authors.forename: Christine
authors.initials: C
authors.lastname: Marie
authors.forename: Thibault
authors.initials: T
authors.lastname: Moreau
authors.forename: Maurice
authors.initials: M
authors.lastname: Giroud
mesh_terms: D017677:Age Distribution; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D004813:Epidemiology / Q000639:trends; D005260:Female; D005602:France / Q000453:epidemiology; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications / Q000453:epidemiology*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D015994:Incidence; D002546:Ischemic Attack, Transient / Q000453:epidemiology* / Q000209:etiology* / Q000517:prevention & control; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications / Q000188:drug therapy / Q000453:epidemiology*; D010865:Pilot Projects; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D011159:Population Surveillance; D012042:Registries / Q000706:statistics & numerical data; D012307:Risk Factors; D017678:Sex Distribution; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology*; D013997:Time Factors
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors